ID   UFO_HUMAN               Reviewed;         894 AA.
AC   P30530; Q8N5L2; Q9UD27;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   16-JUN-2009, sequence version 3.
DT   10-MAY-2017, entry version 188.
DE   RecName: Full=Tyrosine-protein kinase receptor UFO;
DE            EC=2.7.10.1;
DE   AltName: Full=AXL oncogene;
DE   Flags: Precursor;
GN   Name=AXL; Synonyms=UFO;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ASP-266.
RX   PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), VARIANT ASP-266, AND ROLE
RP   IN MYELOID LEUKEMIA.
RC   TISSUE=Fibroblast;
RX   PubMed=1656220; DOI=10.1128/MCB.11.10.5016;
RA   O'Bryan J.P., Frye R.A., Cogswell P.C., Neubauer A., Kitch B.,
RA   Prokop C., Espinosa R., le Beau M.M., Earp H., Liu E.T.;
RT   "AXL, a transforming gene isolated from primary human myeloid leukemia
RT   cells, encodes a novel receptor tyrosine kinase.";
RL   Mol. Cell. Biol. 11:5016-5031(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM LONG), AND VARIANT ASP-266.
RX   PubMed=1834974;
RA   Janssen J.W.G., Schulz A.S., Steenvoorden A.C.M., Schmidberger M.,
RA   Strehl S., Ambros P., Bartram C.R.;
RT   "A novel putative tyrosine kinase receptor with oncogenic potential.";
RL   Oncogene 6:2113-2120(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15057824; DOI=10.1038/nature02399;
RA   Grimwood J., Gordon L.A., Olsen A.S., Terry A., Schmutz J.,
RA   Lamerdin J.E., Hellsten U., Goodstein D., Couronne O., Tran-Gyamfi M.,
RA   Aerts A., Altherr M., Ashworth L., Bajorek E., Black S., Branscomb E.,
RA   Caenepeel S., Carrano A.V., Caoile C., Chan Y.M., Christensen M.,
RA   Cleland C.A., Copeland A., Dalin E., Dehal P., Denys M., Detter J.C.,
RA   Escobar J., Flowers D., Fotopulos D., Garcia C., Georgescu A.M.,
RA   Glavina T., Gomez M., Gonzales E., Groza M., Hammon N., Hawkins T.,
RA   Haydu L., Ho I., Huang W., Israni S., Jett J., Kadner K., Kimball H.,
RA   Kobayashi A., Larionov V., Leem S.-H., Lopez F., Lou Y., Lowry S.,
RA   Malfatti S., Martinez D., McCready P.M., Medina C., Morgan J.,
RA   Nelson K., Nolan M., Ovcharenko I., Pitluck S., Pollard M.,
RA   Popkie A.P., Predki P., Quan G., Ramirez L., Rash S., Retterer J.,
RA   Rodriguez A., Rogers S., Salamov A., Salazar A., She X., Smith D.,
RA   Slezak T., Solovyev V., Thayer N., Tice H., Tsai M., Ustaszewska A.,
RA   Vo N., Wagner M., Wheeler J., Wu K., Xie G., Yang J., Dubchak I.,
RA   Furey T.S., DeJong P., Dickson M., Gordon D., Eichler E.E.,
RA   Pennacchio L.A., Richardson P., Stubbs L., Rokhsar D.S., Myers R.M.,
RA   Rubin E.M., Lucas S.M.;
RT   "The DNA sequence and biology of human chromosome 19.";
RL   Nature 428:529-535(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG), AND VARIANT
RP   ASP-266.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 674-730.
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 677-730, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Colon tumor;
RX   PubMed=7896447; DOI=10.1002/ijc.2910600611;
RA   Craven R.J., Xu L.H., Weiner T.M., Fridell Y.-W., Dent G.A.,
RA   Srivastava S., Varnum B., Liu E.T., Cance W.G.;
RT   "Receptor tyrosine kinases expressed in metastatic colon cancer.";
RL   Int. J. Cancer 60:791-797(1995).
RN   [8]
RP   INTERACTION WITH LIGAND GAS6.
RX   PubMed=7854420; DOI=10.1038/373623a0;
RA   Varnum B.C., Young C., Elliott G., Garcia A., Bartley T.D.,
RA   Fridell Y.W., Hunt R.W., Trail G., Clogston C., Toso R.J.,
RA   Yanagihara D., Bennett L., Silber M., Merewether L.A., Tseng A.,
RA   Escobar E., Liu E.T., Yamane H.K.;
RT   "Axl receptor tyrosine kinase stimulated by the vitamin K-dependent
RT   protein encoded by growth-arrest-specific gene 6.";
RL   Nature 373:623-626(1995).
RN   [9]
RP   INTERACTION WITH GAS6, AND ENZYME REGULATION.
RX   PubMed=8621659; DOI=10.1074/jbc.271.16.9785;
RA   Mark M.R., Chen J., Hammonds R.G., Sadick M., Godowski P.J.;
RT   "Characterization of Gas6, a member of the superfamily of G domain-
RT   containing proteins, as a ligand for Rse and Axl.";
RL   J. Biol. Chem. 271:9785-9789(1996).
RN   [10]
RP   PHOSPHORYLATION AT TYR-779; TYR-821 AND TYR-866, AND INTERACTION WITH
RP   GRB2; LCK; PIK3R1; PIK3R2 AND PLCG1.
RX   PubMed=9178760; DOI=10.1038/sj.onc.1201123;
RA   Braunger J., Schleithoff L., Schulz A.S., Kessler H., Lammers R.,
RA   Ullrich A., Bartram C.R., Janssen J.W.;
RT   "Intracellular signaling of the Ufo/Axl receptor tyrosine kinase is
RT   mediated mainly by a multi-substrate docking-site.";
RL   Oncogene 14:2619-2631(1997).
RN   [11]
RP   ROLE IN PROSTATIC CARCINOMA.
RX   PubMed=10403904; DOI=10.1046/j.1525-1500.1999.99034.x;
RA   Jacob A.N., Kalapurakal J., Davidson W.R., Kandpal G., Dunson N.,
RA   Prashar Y., Kandpal R.P.;
RT   "A receptor tyrosine kinase, UFO/Axl, and other genes isolated by a
RT   modified differential display PCR are overexpressed in metastatic
RT   prostatic carcinoma cell line DU145.";
RL   Cancer Detect. Prev. 23:325-332(1999).
RN   [12]
RP   ROLE IN BREAST CANCER.
RX   PubMed=11484958; DOI=10.1023/A:1011126330233;
RA   Berclaz G., Altermatt H.J., Rohrbach V., Kieffer I., Dreher E.,
RA   Andres A.C.;
RT   "Estrogen dependent expression of the receptor tyrosine kinase axl in
RT   normal and malignant human breast.";
RL   Ann. Oncol. 12:819-824(2001).
RN   [13]
RP   INTERACTION WITH NCK2; PIK3R3; SOCS1 AND TNS2.
RX   PubMed=12470648; DOI=10.1016/S0006-291X(02)02718-3;
RA   Hafizi S., Alindri F., Karlsson R., Dahlbaeck B.;
RT   "Interaction of Axl receptor tyrosine kinase with C1-TEN, a novel C1
RT   domain-containing protein with homology to tensin.";
RL   Biochem. Biophys. Res. Commun. 299:793-800(2002).
RN   [14]
RP   FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY.
RX   PubMed=12364394; DOI=10.1161/01.RES.0000036753.50601.E9;
RA   D'Arcangelo D., Gaetano C., Capogrossi M.C.;
RT   "Acidification prevents endothelial cell apoptosis by Axl
RT   activation.";
RL   Circ. Res. 91:E4-12(2002).
RN   [15]
RP   ROLE IN THYROID CARCINOMAS.
RX   PubMed=12490074; DOI=10.1089/105072502320908303;
RA   Ito M., Nakashima M., Nakayama T., Ohtsuru A., Nagayama Y.,
RA   Takamura N., Demedchik E.P., Sekine I., Yamashita S.;
RT   "Expression of receptor-type tyrosine kinase, Axl, and its ligand,
RT   Gas6, in pediatric thyroid carcinomas around Chernobyl.";
RL   Thyroid 12:971-975(2002).
RN   [16]
RP   INTERACTION WITH CBL AND GAS6, AND UBIQUITINATION.
RX   PubMed=15958209; DOI=10.1016/j.bbrc.2005.05.086;
RA   Valverde P.;
RT   "Effects of Gas6 and hydrogen peroxide in Axl ubiquitination and
RT   downregulation.";
RL   Biochem. Biophys. Res. Commun. 333:180-185(2005).
RN   [17]
RP   ENZYME REGULATION, AND FUNCTION.
RX   PubMed=15507525; DOI=10.1182/blood-2004-04-1469;
RA   Gallicchio M., Mitola S., Valdembri D., Fantozzi R., Varnum B.,
RA   Avanzi G.C., Bussolino F.;
RT   "Inhibition of vascular endothelial growth factor receptor 2-mediated
RT   endothelial cell activation by Axl tyrosine kinase receptor.";
RL   Blood 105:1970-1976(2005).
RN   [18]
RP   FUNCTION IN PLATELET ACTIVATION AND THROMBOTIC RESPONSE REGULATION.
RX   PubMed=15733062; DOI=10.1111/j.1538-7836.2005.01186.x;
RA   Gould W.R., Baxi S.M., Schroeder R., Peng Y.W., Leadley R.J.,
RA   Peterson J.T., Perrin L.A.;
RT   "Gas6 receptors Axl, Sky and Mer enhance platelet activation and
RT   regulate thrombotic responses.";
RL   J. Thromb. Haemost. 3:733-741(2005).
RN   [19]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=17005688; DOI=10.1128/JVI.01157-06;
RA   Shimojima M., Takada A., Ebihara H., Neumann G., Fujioka K.,
RA   Irimura T., Jones S., Feldmann H., Kawaoka Y.;
RT   "Tyro3 family-mediated cell entry of Ebola and Marburg viruses.";
RL   J. Virol. 80:10109-10116(2006).
RN   [20]
RP   INTERACTION WITH GRB2; PIK3R1 AND PIK3R2, AND PHOSPHORYLATION AT
RP   TYR-779; TYR-821 AND TYR-866.
RX   PubMed=18346204; DOI=10.1111/j.1471-4159.2008.05343.x;
RA   Weinger J.G., Gohari P., Yan Y., Backer J.M., Varnum B.,
RA   Shafit-Zagardo B.;
RT   "In brain, Axl recruits Grb2 and the p85 regulatory subunit of PI3
RT   kinase; in vitro mutagenesis defines the requisite binding sites for
RT   downstream Akt activation.";
RL   J. Neurochem. 106:134-146(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-884, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   FUNCTION OF THE GAS6/AXL SIGNALING PATHWAY.
RX   PubMed=18840707; DOI=10.1182/blood-2008-05-157073;
RA   Park I.K., Giovenzana C., Hughes T.L., Yu J., Trotta R.,
RA   Caligiuri M.A.;
RT   "The Axl/Gas6 pathway is required for optimal cytokine signaling
RT   during human natural killer cell development.";
RL   Blood 113:2470-2477(2009).
RN   [23]
RP   INTERACTION WITH GRB2 AND TNK2.
RX   PubMed=19815557; DOI=10.1074/jbc.M109.072660;
RA   Pao-Chun L., Chan P.M., Chan W., Manser E.;
RT   "Cytoplasmic ACK1 interaction with multiple receptor tyrosine kinases
RT   is mediated by Grb2: an analysis of ACK1 effects on Axl signaling.";
RL   J. Biol. Chem. 284:34954-34963(2009).
RN   [24]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=21501828; DOI=10.1016/j.chom.2011.03.012;
RA   Morizono K., Xie Y., Olafsen T., Lee B., Dasgupta A., Wu A.M.,
RA   Chen I.S.;
RT   "The soluble serum protein Gas6 bridges virion envelope
RT   phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate
RT   viral entry.";
RL   Cell Host Microbe 9:286-298(2011).
RN   [25]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=22156524; DOI=10.1128/JVI.06451-11;
RA   Shimojima M., Stroher U., Ebihara H., Feldmann H., Kawaoka Y.;
RT   "Identification of cell surface molecules involved in dystroglycan-
RT   independent Lassa virus cell entry.";
RL   J. Virol. 86:2067-2078(2012).
RN   [26]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=22673088; DOI=10.1292/jvms.12-0176;
RA   Shimojima M., Kawaoka Y.;
RT   "Cell surface molecules involved in infection mediated by lymphocytic
RT   choriomeningitis virus glycoprotein.";
RL   J. Vet. Med. Sci. 74:1363-1366(2012).
RN   [27]
RP   FUNCTION (MICROBIAL INFECTION), AND REVIEW.
RX   PubMed=25277499; DOI=10.1016/j.virol.2014.09.009;
RA   Moller-Tank S., Maury W.;
RT   "Phosphatidylserine receptors: enhancers of enveloped virus entry and
RT   infection.";
RL   Virology 468:565-580(2014).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (3.3 ANGSTROMS) OF 33-227 IN COMPLEX WITH GAS6,
RP   MUTAGENESIS OF GLU-63; GLU-66 AND THR-84, AND SUBUNIT.
RX   PubMed=16362042; DOI=10.1038/sj.emboj.7600912;
RA   Sasaki T., Knyazev P.G., Clout N.J., Cheburkin Y., Goehring W.,
RA   Ullrich A., Timpl R., Hohenester E.;
RT   "Structural basis for Gas6-Axl signalling.";
RL   EMBO J. 25:80-87(2006).
RN   [29]
RP   VARIANTS [LARGE SCALE ANALYSIS] MET-112; TRP-295; CYS-499 AND GLY-515.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Receptor tyrosine kinase that transduces signals from
CC       the extracellular matrix into the cytoplasm by binding growth
CC       factor GAS6 and which is thus regulating many physiological
CC       processes including cell survival, cell proliferation, migration
CC       and differentiation. Ligand binding at the cell surface induces
CC       dimerization and autophosphorylation of AXL. Following activation
CC       by ligand, ALX binds and induces tyrosine phosphorylation of PI3-
CC       kinase subunits PIK3R1, PIK3R2 and PIK3R3; but also GRB2, PLCG1,
CC       LCK and PTPN11. Other downstream substrate candidates for AXL are
CC       CBL, NCK2, SOCS1 and TNS2. Recruitment of GRB2 and
CC       phosphatidylinositol 3 kinase regulatory subunits by AXL leads to
CC       the downstream activation of the AKT kinase. GAS6/AXL signaling
CC       plays a role in various processes such as endothelial cell
CC       survival during acidification by preventing apoptosis, optimal
CC       cytokine signaling during human natural killer cell development,
CC       hepatic regeneration, gonadotropin-releasing hormone neuron
CC       survival and migration, platelet activation, or regulation of
CC       thrombotic responses. Plays also an important role in inhibition
CC       of Toll-like receptors (TLRs)-mediated innate immune response.
CC       {ECO:0000269|PubMed:10403904, ECO:0000269|PubMed:11484958,
CC       ECO:0000269|PubMed:12364394, ECO:0000269|PubMed:12490074,
CC       ECO:0000269|PubMed:15507525, ECO:0000269|PubMed:15733062,
CC       ECO:0000269|PubMed:1656220, ECO:0000269|PubMed:18840707}.
CC   -!- FUNCTION: (Microbial infection) Acts as a receptor for lassa virus
CC       and lymphocytic choriomeningitis virus, possibly through GAS6
CC       binding to phosphatidyl-serine at the surface of virion envelope
CC       (PubMed:22156524, PubMed:22673088, PubMed:25277499,
CC       PubMed:21501828). Acts as a receptor for ebolavirus, possibly
CC       through GAS6 binding to phosphatidyl-serine at the surface of
CC       virion envelope (PubMed:17005688). {ECO:0000269|PubMed:17005688,
CC       ECO:0000269|PubMed:21501828, ECO:0000269|PubMed:22156524,
CC       ECO:0000269|PubMed:22673088, ECO:0000269|PubMed:25277499}.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10028}.
CC   -!- ENZYME REGULATION: Activated by GAS6-binding and subsequent
CC       autophosphorylation. {ECO:0000269|PubMed:15507525,
CC       ECO:0000269|PubMed:8621659}.
CC   -!- SUBUNIT: Heterodimer and heterotetramer with ligand GAS6.
CC       Interacts with CBL, GRB2, LCK, NCK2, PIK3R1, PIK3R2, PIK3R3,
CC       PLCG1, SOCS1 and TNS2. Part of a complex including AXL, TNK2 and
CC       GRB2, in which GRB2 promotes AXL recruitment by TNK2.
CC       {ECO:0000269|PubMed:12470648, ECO:0000269|PubMed:15958209,
CC       ECO:0000269|PubMed:16362042, ECO:0000269|PubMed:18346204,
CC       ECO:0000269|PubMed:19815557, ECO:0000269|PubMed:7854420,
CC       ECO:0000269|PubMed:8621659, ECO:0000269|PubMed:9178760}.
CC   -!- INTERACTION:
CC       P00533:EGFR; NbExp=4; IntAct=EBI-2850927, EBI-297353;
CC       Q14393:GAS6; NbExp=8; IntAct=EBI-2850927, EBI-2802811;
CC       P62993:GRB2; NbExp=3; IntAct=EBI-2850927, EBI-401755;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:7896447};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:7896447}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P30530-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P30530-2; Sequence=VSP_005017;
CC   -!- TISSUE SPECIFICITY: Highly expressed in metastatic colon tumors.
CC       Expressed in primary colon tumors. Weakly expressed in normal
CC       colon tissue. {ECO:0000269|PubMed:7896447}.
CC   -!- PTM: Monoubiquitinated upon GAS6-binding. A very small proportion
CC       of the receptor could be subjected to polyubiquitination in a very
CC       transient fashion. {ECO:0000269|PubMed:15958209}.
CC   -!- PTM: Phosphorylated at tyrosine residues by autocatalysis, which
CC       activates kinase activity. {ECO:0000269|PubMed:18346204,
CC       ECO:0000269|PubMed:9178760}.
CC   -!- DISEASE: Note=AXL and its ligand GAS6 are highly expressed in
CC       thyroid carcinoma tissues, and might thus be involved in thyroid
CC       tumorigenesis. Overexpression of AXL and its ligand was also
CC       detected in many other cancers such as myeloproliferative
CC       disorders, prostatic carcinoma cells, or breast cancer.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. AXL/UFO subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/AXLID733ch19q13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M76125; AAA61243.1; -; mRNA.
DR   EMBL; S65125; AAB20305.1; -; mRNA.
DR   EMBL; X57019; CAA40338.1; -; mRNA.
DR   EMBL; AC011510; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC032229; AAH32229.1; -; mRNA.
DR   CCDS; CCDS12574.1; -. [P30530-2]
DR   CCDS; CCDS12575.1; -. [P30530-1]
DR   PIR; A41527; A41527.
DR   RefSeq; NP_001690.2; NM_001699.5.
DR   RefSeq; NP_068713.2; NM_021913.4.
DR   UniGene; Hs.590970; -.
DR   PDB; 2C5D; X-ray; 3.30 A; C/D=33-227.
DR   PDB; 4RA0; X-ray; 3.07 A; C/D=33-227.
DR   PDBsum; 2C5D; -.
DR   PDBsum; 4RA0; -.
DR   ProteinModelPortal; P30530; -.
DR   SMR; P30530; -.
DR   BioGrid; 107036; 17.
DR   IntAct; P30530; 16.
DR   MINT; MINT-2735752; -.
DR   STRING; 9606.ENSP00000301178; -.
DR   BindingDB; P30530; -.
DR   ChEMBL; CHEMBL4895; -.
DR   GuidetoPHARMACOLOGY; 1835; -.
DR   iPTMnet; P30530; -.
DR   PhosphoSitePlus; P30530; -.
DR   BioMuta; AXL; -.
DR   DMDM; 239938818; -.
DR   EPD; P30530; -.
DR   MaxQB; P30530; -.
DR   PaxDb; P30530; -.
DR   PeptideAtlas; P30530; -.
DR   PRIDE; P30530; -.
DR   DNASU; 558; -.
DR   Ensembl; ENST00000301178; ENSP00000301178; ENSG00000167601.
DR   Ensembl; ENST00000359092; ENSP00000351995; ENSG00000167601.
DR   GeneID; 558; -.
DR   KEGG; hsa:558; -.
DR   UCSC; uc010ehj.5; human. [P30530-1]
DR   CTD; 558; -.
DR   DisGeNET; 558; -.
DR   GeneCards; AXL; -.
DR   HGNC; HGNC:905; AXL.
DR   HPA; CAB032501; -.
DR   HPA; HPA037422; -.
DR   HPA; HPA037423; -.
DR   MIM; 109135; gene.
DR   neXtProt; NX_P30530; -.
DR   PharmGKB; PA25197; -.
DR   eggNOG; ENOG410IG6I; Eukaryota.
DR   eggNOG; COG0515; LUCA.
DR   HOGENOM; HOG000231685; -.
DR   HOVERGEN; HBG006346; -.
DR   InParanoid; P30530; -.
DR   KO; K05115; -.
DR   OrthoDB; EOG091G016X; -.
DR   PhylomeDB; P30530; -.
DR   TreeFam; TF317402; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   Reactome; R-HSA-4420097; VEGFA-VEGFR2 Pathway.
DR   SignaLink; P30530; -.
DR   SIGNOR; P30530; -.
DR   ChiTaRS; AXL; human.
DR   EvolutionaryTrace; P30530; -.
DR   GeneWiki; AXL_receptor_tyrosine_kinase; -.
DR   GenomeRNAi; 558; -.
DR   PRO; PR:P30530; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000167601; -.
DR   CleanEx; HS_AXL; -.
DR   ExpressionAtlas; P30530; baseline and differential.
DR   Genevisible; P30530; HS.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0044228; C:host cell surface; IDA:CACAO.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005622; C:intracellular; IEA:GOC.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0032036; F:myosin heavy chain binding; IEA:Ensembl.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IEA:Ensembl.
DR   GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; IEA:Ensembl.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; EXP:Reactome.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0001618; F:virus receptor activity; IEA:UniProtKB-KW.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0043277; P:apoptotic cell clearance; IEA:Ensembl.
DR   GO; GO:0001974; P:blood vessel remodeling; IEA:Ensembl.
DR   GO; GO:0048469; P:cell maturation; IEP:UniProtKB.
DR   GO; GO:0031668; P:cellular response to extracellular stimulus; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0035457; P:cellular response to interferon-alpha; IDA:UniProtKB.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0097028; P:dendritic cell differentiation; IEP:UniProtKB.
DR   GO; GO:0034101; P:erythrocyte homeostasis; IEA:Ensembl.
DR   GO; GO:0021885; P:forebrain cell migration; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0045087; P:innate immune response; IEA:UniProtKB-KW.
DR   GO; GO:0001779; P:natural killer cell differentiation; IEA:Ensembl.
DR   GO; GO:2000669; P:negative regulation of dendritic cell apoptotic process; IDA:UniProtKB.
DR   GO; GO:0032689; P:negative regulation of interferon-gamma production; IDA:UniProtKB.
DR   GO; GO:0051250; P:negative regulation of lymphocyte activation; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0032720; P:negative regulation of tumor necrosis factor production; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0097350; P:neutrophil clearance; IEA:Ensembl.
DR   GO; GO:0042698; P:ovulation cycle; IEA:Ensembl.
DR   GO; GO:0006909; P:phagocytosis; IDA:UniProtKB.
DR   GO; GO:0030168; P:platelet activation; IEA:Ensembl.
DR   GO; GO:0001961; P:positive regulation of cytokine-mediated signaling pathway; IDA:UniProtKB.
DR   GO; GO:0032825; P:positive regulation of natural killer cell differentiation; IDA:UniProtKB.
DR   GO; GO:0048549; P:positive regulation of pinocytosis; IMP:CACAO.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0043491; P:protein kinase B signaling; IEA:Ensembl.
DR   GO; GO:0032940; P:secretion by cell; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0034446; P:substrate adhesion-dependent cell spreading; IEA:Ensembl.
DR   GO; GO:0060068; P:vagina development; IEA:Ensembl.
DR   GO; GO:0048010; P:vascular endothelial growth factor receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0046718; P:viral entry into host cell; IMP:CACAO.
DR   CDD; cd00063; FN3; 2.
DR   Gene3D; 2.60.40.10; -; 4.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF00041; fn3; 2.
DR   Pfam; PF07714; Pkinase_Tyr; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 2.
DR   SMART; SM00409; IG; 2.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF49265; SSF49265; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50853; FN3; 2.
DR   PROSITE; PS50835; IG_LIKE; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell membrane;
KW   Complete proteome; Differentiation; Disulfide bond; Glycoprotein;
KW   Host cell receptor for virus entry; Host-virus interaction; Immunity;
KW   Immunoglobulin domain; Innate immunity; Kinase; Membrane;
KW   Nucleotide-binding; Oncogene; Phosphoprotein; Polymorphism;
KW   Proto-oncogene; Receptor; Reference proteome; Repeat; Signal;
KW   Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL        1     25       {ECO:0000255}.
FT   CHAIN        26    894       Tyrosine-protein kinase receptor UFO.
FT                                /FTId=PRO_0000024481.
FT   TOPO_DOM     26    451       Extracellular. {ECO:0000255}.
FT   TRANSMEM    452    472       Helical. {ECO:0000255}.
FT   TOPO_DOM    473    894       Cytoplasmic. {ECO:0000255}.
FT   DOMAIN       27    128       Ig-like C2-type 1.
FT   DOMAIN      139    222       Ig-like C2-type 2.
FT   DOMAIN      227    331       Fibronectin type-III 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      336    428       Fibronectin type-III 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00316}.
FT   DOMAIN      536    807       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     542    550       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       26     92       Interaction with GAS6.
FT   ACT_SITE    672    672       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10028}.
FT   BINDING     567    567       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     703    703       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     779    779       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18346204,
FT                                ECO:0000269|PubMed:9178760}.
FT   MOD_RES     821    821       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18346204,
FT                                ECO:0000269|PubMed:9178760}.
FT   MOD_RES     866    866       Phosphotyrosine; by autocatalysis.
FT                                {ECO:0000269|PubMed:18346204,
FT                                ECO:0000269|PubMed:9178760}.
FT   MOD_RES     884    884       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   CARBOHYD     43     43       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    157    157       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    198    198       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    339    339       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    345    345       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    401    401       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     56    117       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   DISULFID    160    205       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ     429    437       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:1656220}.
FT                                /FTId=VSP_005017.
FT   VARIANT     112    112       T -> M (in dbSNP:rs35202236).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_045596.
FT   VARIANT     266    266       N -> D (in dbSNP:rs7249222).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:1656220,
FT                                ECO:0000269|PubMed:1834974,
FT                                ECO:0000269|PubMed:2247464}.
FT                                /FTId=VAR_057990.
FT   VARIANT     295    295       R -> W (in a lung neuroendocrine
FT                                carcinoma sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_045597.
FT   VARIANT     499    499       R -> C (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041877.
FT   VARIANT     515    515       S -> G. {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041878.
FT   MUTAGEN      63     63       E->R: Slightly reduced affinity for GAS6.
FT                                {ECO:0000269|PubMed:16362042}.
FT   MUTAGEN      66     66       E->R: Reduced affinity for GAS6.
FT                                {ECO:0000269|PubMed:16362042}.
FT   MUTAGEN      84     84       T->R: Reduced affinity for GAS6.
FT                                {ECO:0000269|PubMed:16362042}.
FT   CONFLICT    303    303       T -> P (in Ref. 3; AAB20305/CAA40338).
FT                                {ECO:0000305}.
FT   CONFLICT    338    338       E -> K (in Ref. 2; AAA61243).
FT                                {ECO:0000305}.
FT   CONFLICT    430    430       Q -> E (in Ref. 3; AAB20305/CAA40338).
FT                                {ECO:0000305}.
FT   CONFLICT    639    639       D -> G (in Ref. 3; AAB20305/CAA40338).
FT                                {ECO:0000305}.
FT   CONFLICT    696    696       K -> I (in Ref. 7; no nucleotide entry).
FT                                {ECO:0000305}.
FT   CONFLICT    764    764       Q -> R (in Ref. 5; AAH32229).
FT                                {ECO:0000305}.
FT   STRAND       37     39       {ECO:0000244|PDB:4RA0}.
FT   STRAND       44     46       {ECO:0000244|PDB:4RA0}.
FT   STRAND       52     63       {ECO:0000244|PDB:4RA0}.
FT   STRAND       67     71       {ECO:0000244|PDB:4RA0}.
FT   STRAND       80    106       {ECO:0000244|PDB:4RA0}.
FT   HELIX       109    111       {ECO:0000244|PDB:4RA0}.
FT   STRAND      113    121       {ECO:0000244|PDB:4RA0}.
FT   STRAND      124    127       {ECO:0000244|PDB:4RA0}.
FT   STRAND      131    135       {ECO:0000244|PDB:4RA0}.
FT   STRAND      140    143       {ECO:0000244|PDB:4RA0}.
FT   STRAND      148    150       {ECO:0000244|PDB:4RA0}.
FT   STRAND      156    159       {ECO:0000244|PDB:4RA0}.
FT   STRAND      161    163       {ECO:0000244|PDB:4RA0}.
FT   STRAND      165    167       {ECO:0000244|PDB:4RA0}.
FT   STRAND      170    175       {ECO:0000244|PDB:4RA0}.
FT   STRAND      178    187       {ECO:0000244|PDB:4RA0}.
FT   STRAND      190    194       {ECO:0000244|PDB:4RA0}.
FT   STRAND      201    209       {ECO:0000244|PDB:4RA0}.
FT   STRAND      212    215       {ECO:0000244|PDB:4RA0}.
FT   STRAND      219    223       {ECO:0000244|PDB:4RA0}.
SQ   SEQUENCE   894 AA;  98336 MW;  2C2D3574EADA4116 CRC64;
     MAWRCPRMGR VPLAWCLALC GWACMAPRGT QAEESPFVGN PGNITGARGL TGTLRCQLQV
     QGEPPEVHWL RDGQILELAD STQTQVPLGE DEQDDWIVVS QLRITSLQLS DTGQYQCLVF
     LGHQTFVSQP GYVGLEGLPY FLEEPEDRTV AANTPFNLSC QAQGPPEPVD LLWLQDAVPL
     ATAPGHGPQR SLHVPGLNKT SSFSCEAHNA KGVTTSRTAT ITVLPQQPRN LHLVSRQPTE
     LEVAWTPGLS GIYPLTHCTL QAVLSNDGMG IQAGEPDPPE EPLTSQASVP PHQLRLGSLH
     PHTPYHIRVA CTSSQGPSSW THWLPVETPE GVPLGPPENI SATRNGSQAF VHWQEPRAPL
     QGTLLGYRLA YQGQDTPEVL MDIGLRQEVT LELQGDGSVS NLTVCVAAYT AAGDGPWSLP
     VPLEAWRPGQ AQPVHQLVKE PSTPAFSWPW WYVLLGAVVA AACVLILALF LVHRRKKETR
     YGEVFEPTVE RGELVVRYRV RKSYSRRTTE ATLNSLGISE ELKEKLRDVM VDRHKVALGK
     TLGEGEFGAV MEGQLNQDDS ILKVAVKTMK IAICTRSELE DFLSEAVCMK EFDHPNVMRL
     IGVCFQGSER ESFPAPVVIL PFMKHGDLHS FLLYSRLGDQ PVYLPTQMLV KFMADIASGM
     EYLSTKRFIH RDLAARNCML NENMSVCVAD FGLSKKIYNG DYYRQGRIAK MPVKWIAIES
     LADRVYTSKS DVWSFGVTMW EIATRGQTPY PGVENSEIYD YLRQGNRLKQ PADCLDGLYA
     LMSRCWELNP QDRPSFTELR EDLENTLKAL PPAQEPDEIL YVNMDEGGGY PEPPGAAGGA
     DPPTQPDPKD SCSCLTAAEV HPAGRYVLCP STTPSPAQPA DRGSPAAPGQ EDGA
//
